16D0 McMahon, Steven - Thomas Jefferson University - Thomas Jefferson University

Steven B. McMahon, PhD

Contact Dr. McMahon

Kimmel Cancer Center
233 S. Tenth Street, Suite 609
Philadelphia, PA 19107

(215) 503-9064

Most Recent Peer-reviewed Publications

  1. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  2. Retraction Notice to: Nuclear receptor function requires a TFTC-type histone acetyl transferase complex
  3. MYC and the control of apoptosis
  4. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression
  5. The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2)
  6. P53: The TRiC Is Knowing When to Fold 'Em
  7. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer
  8. Dachshund binds p53 to block the growth of lung adenocarcinoma cells
  9. A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex
  10. Dynamic regulation of mitochondrial transcription as a mechanism of cellular adaptation
  11. MYST protein acetyltransferase activity requires active site lysine autoacetylation
  12. Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC
  13. Enzymatic assays for assessing histone deubiquitylation activity
  14. Phosphorylation of Tip60 by GSK-3 Determines the Induction of PUMA and Apoptosis by p53
  15. The Role of Epigenetic Modifications in Cancer
  16. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a
  17. Regulation of microRNA-145 by growth arrest and differentiation
  18. Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis
  19. Emerging concepts in the analysis of transcriptional targets of the MYC oncoprotein: Are the targets targetable?
  20. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase